Zambian patients on dolutegravir and recycled tenofovir regimens have high risk of TB even after switch
Many monkeypox cases among men living with HIV, but no sign yet of poorer outcomes
Giving antibodies to prevent vertical transmission in Africa would be cost-effective or even save money, study finds
Community organisations have formed the backbone of the HIV response in Ukraine
European Commission approves first twice-yearly HIV medication
Long-term Canadian study shows HIV-exposed children have worse health outcomes
Vitamin D and calcium supplements suggested to avert bone disease in people taking tenofovir-based ART and PrEP
Long-acting cabotegravir and rilpivirine may be feasible for people without viral suppression
A cure must be a cure for all: why more HIV cure research in Africa is needed
